sition to continue to execute on our strategies including investments in acquisitions that provide long-term growth for the Company and its shareholders," said Paul Bisaro, President and CEO. "We saw continued growth in our Global Generics and Global Brands businesses, driven largely by key product launches throughout the year. In 2011, we launched 189 generic products globally, with significant revenue contributions from the U.S. launches of generic versions of Concerta®, Seasonique®, Kadian® and Lipitor®. Investments in our future growth resulted in the filing of 30 new Abbreviated New Drug Applications in the U.S. and more than 130 applications globally."
"In our Global Brands business, we experienced growth from U.S. sales of Rapaflo®, Gelnique® and Crinone®; launched Generess® Fe and Androderm® 2mg, 4mg in the U.S.; and focusing on the long-term future of this business, announced a collaboration with Amgen to develop a portfolio of biosimilar monoclonal antibody (mAb) oncology products," Bisaro continued.
"In 2011, we also continued to utilize our strong balance sheet to expand our global footprint by investing in key growth markets with the expansion of our brand business in Canada and the addition of Specifar Pharmaceuticals to our European operations. We also realized significant enhancements to our global supply chain through our Operational Excellence framework and announced expansions to our Goa, Malta and Salt Lake City facilities," concluded Bisaro. Fourth Quarter and Full Year 2011 Business Segment ResultsGlobal Generics Segment InformationThree Months EndedTwelve Months EndedDecember 31,December 31,(Unaudited; $ in millions)
1,172.3646.03,367.22,338.4Operating expenses:Cost of sales
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine technology :1
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Watson Launches Generic Biaxin(R) XL2
. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder3
. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia4
. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder5
. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)6
. Watson and Barr Settle Lawsuit Over Oxytrol(R)7
. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook8
. Watson Completes Acquisition of Eden Biodesign9
. Watson to Present at Credit Suisse Healthcare Conference10
. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy11
. Watson Files FDA Application for Generic Rozerem(R)